Details

Autor(en) / Beteiligte

• Provencio, Mariano
• Cruz Mora, Miguel Á.
• Gómez-Codina, José
• Quero Blanco, Cristina
• Llanos, Marta
• García-Arroyo, Francisco R.
• de la Cruz, Luis
• Gumá Padró, Josep
• Delgado Pérez, Juan R.
• Sánchez, Antonio
• Álvarez Cabellos, Ruth
• Rueda, Antonio

Titel

Consolidation treatment with Yttrium-90 ibritumomab tiuxetan after new induction regimen in patients with intermediate- and high-risk follicular lymphoma according to the follicular lymphoma international prognostic index: a multicenter, prospective phase II trial of the Spanish Lymphoma Oncology Group

Ist Teil von

• Leukemia & lymphoma, 2014-01, Vol.55 (1), p.51-55

Ort / Verlag

United States: Informa Healthcare

Erscheinungsjahr

2014

Quelle

Taylor & Francis Journals Auto-Holdings Collection

Beschreibungen/Notizen

• Abstract Relapse is the main cause of therapeutic failure in follicular lymphoma (FL). We set out to evaluate the role of consolidation with Yttrium-90 ibritumomab tiuxetan in patients with intermediate- and high-risk FL after four cycles of CHOP-R (cyclophosphamide, doxorubicin, vincristine, prednisone, rituximab) and two cycles of CHOP. Thirty patients were included. The overall response rate after consolidation therapy was 93%. Of the 18 patients who presented with a partial response after induction treatment, 11 had a complete response after consolidation treatment. The complete clinical response rate was 76.6%. The most important grade 3-4 toxicity was hematological, with 46% thrombopenia and 56% neutropenia. With a median follow-up of 26 months, the means for progression-free survival and overall survival were not reached. Our data support consolidation with Yttrium-90 ibritumomab tiuxetan as an effective treatment, which provides long progression-free and overall survival, in first line after a response to induction treatment in patients with intermediate- and high-risk FL.